Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

被引：4

作者：

Duerr, Donat ^{[1
]}

Siciliano, Raffaele Daniele ^{[1
]}

Hummel, Yvonne ^{[1
]}

O'Meara, Alix ^{[1
]}

Hirschi, Anita ^{[1
]}

Burkhard, Roger ^{[1
]}

Honegger, Hanspeter ^{[1
]}

机构：

[1] Stadtspital Triemli, CH-8063 Zurich, Switzerland

来源：

ANNALS OF HEMATOLOGY | 2010年 / 89卷 / 01期

关键词：

DELETION; MANAGEMENT; DEL(5Q);

D O I：

10.1007/s00277-009-0775-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：105 / 106

页数：2

共 42 条

[31] 5q-syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide [J].

Ortega, Margarita ;

Mallo, Mar ;

Sole, Francesc ;

Sanchez-Morata, Carmen ;

Lopez-Andreoni, Laura ;

Martinez-Morgado, Noemi ;

Gironella, Mercedes ;

Valcarcel, David ;

Vallespi, Teresa .

LEUKEMIA RESEARCH, 2013, 37 (10) :1248-1250

[32] Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide [J].

Zou, Ying S. ;

Fink, Stephanie R. ;

Stockero, Kimberly J. ;

Paternoster, Sarah F. ;

Smoley, Stephanie A. ;

Tun, Han W. ;

Reeder, Craig B. ;

Tefferi, Ayalew ;

Dewald, Gordon W. .

LEUKEMIA RESEARCH, 2007, 31 (09) :1185-1189

[33] Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm [J].

Gharaee, Nadia ;

Wegrzyn-Woltosz, Joanna ;

Jiang, Jihong ;

Akhade, Vijay Suresh ;

Bridgers, Joshua ;

Stubbins, Ryan J. ;

Hiwase, Devendra ;

Kutyna, Monika M. ;

Chan, Onyee ;

Komrokji, Rami ;

Padron, Eric ;

Deng, Yu ;

Cole, Gary ;

Umlandt, Patricia ;

Fuller, Megan ;

Kim, Ada ;

Karsan, Aly .

LEUKEMIA, 2025, :917-928

[34] p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) [J].

Saft, Leonie ;

Karimi, Mohsen ;

Ghaderi, Mehran ;

Matolcsy, Andras ;

Mufti, Ghulam J. ;

Kulasekararaj, Austin ;

Goehring, Gudrun ;

Giagounidis, Aristoteles ;

Selleslag, Dominik ;

Muus, Petra ;

Sanz, Guillermo ;

Mittelman, Moshe ;

Bowen, David ;

Porwit, Anna ;

Fu, Tommy ;

Backstrom, Jay ;

Fenaux, Pierre ;

MacBeth, Kyle J. ;

Hellstrom-Lindberg, Eva .

HAEMATOLOGICA, 2014, 99 (06) :1041-1049

[35] Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission [J].

Ades, L. ;

Eclache, V. ;

Gardin, C. ;

Boehrer, S. ;

Leroux, G. ;

Martiat, P. ;

Fenaux, P. .

BONE MARROW TRANSPLANTATION, 2010, 45 (04) :791-792

[36] TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q) [J].

Tefferi, Ayalew ;

Fleti, Farah ;

Chan, Onyee ;

Al Ali, Najla H. ;

Al-Kali, Aref ;

Begna, Kebede H. ;

Foran, James M. ;

Badar, Talha ;

Khera, Nandita ;

Shah, Mithun ;

Hiwase, Devendra ;

Padron, Eric ;

Sallman, David A. ;

Pardanani, Animesh ;

Arber, Daniel A. ;

Orazi, Attilio ;

Reichard, Kaaren K. ;

He, Rong ;

Ketterling, Rhett P. ;

Gangat, Naseema ;

Komrokji, Rami .

BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) :1243-1248

[37] Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities [J].

Mollgard, Lars ;

Saft, Leonie ;

Treppendahl, Marianne Bach ;

Dybedal, Ingunn ;

Norgaard, Jan Maxwell ;

Astermark, Jan ;

Ejerblad, Elisabeth ;

Garelius, Hege ;

Dufva, Inge Hogh ;

Jansson, Monika ;

Jadersten, Martin ;

Kjeldsen, Lars ;

Linder, Olle ;

Nilsson, Lars ;

Vestergaard, Hanne ;

Porwit, Anna ;

Gronbaek, Kirsten ;

Lindberg, Eva Hellstrom .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (07) :963-971

[38] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS [J].

List, A. F. ;

Bennett, J. M. ;

Sekeres, M. A. ;

Skikne, B. ;

Fu, T. ;

Shammo, J. M. ;

Nimer, S. D. ;

Knight, R. D. ;

Giagounidis, A. .

LEUKEMIA, 2014, 28 (05) :1033-1040

[39] Diagnosis of del(5q) MDS, 14 Years after JAK-2 Positive PV Appearance: Complete Remission of both Diseases with Lenalidomide Monotherapy [J].

Vaccarino, Antonella ;

Dogliotti, Irene ;

Marletto, Fabio ;

Demarchi, Andrea ;

Bazzan, Mario .

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2016, 8

[40] Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression [J].

Goehring, Gudrun ;

Giagounidis, Aristoteles ;

Buesche, Guntram ;

Kreipe, Hans Heinrich ;

Zimmermann, Martin ;

Hellstroem-Lindberg, Eva ;

Aul, Carlo ;

Schlegelberger, Brigitte .

ANNALS OF HEMATOLOGY, 2010, 89 (04) :365-374

← 1 2 3 4 5 →